ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
4.090
+0.020 (0.49%)
At close: Oct 24, 2025, 4:00 PM EDT
4.200
+0.110 (2.69%)
After-hours: Oct 24, 2025, 7:23 PM EDT
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $18.84M in the quarter ending June 30, 2025, with 8.21% growth. This brings the company's revenue in the last twelve months to $77.25M, up 15.73% year-over-year. In the year 2024, ADC Therapeutics had annual revenue of $70.84M with 1.84% growth.
Revenue (ttm)
$77.25M
Revenue Growth
+15.73%
P/S Ratio
5.71
Revenue / Employee
$291,494
Employees
265
Market Cap
460.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.84M | 1.28M | 1.84% |
| Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
| Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
| Dec 31, 2021 | 33.92M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ADCT News
- 12 days ago - ADC Therapeutics Announces $60 Million Private Placement - PRNewsWire
- 24 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 2 months ago - ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 - PRNewsWire
- 2 months ago - ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - PRNewsWire
- 2 months ago - ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 - PRNewsWire
- 4 months ago - ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - PRNewsWire
- 4 months ago - ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) - PRNewsWire